Abstract
Tumor necrosis factor (TNF) inhibitor therapies (anti-TNFs) are used routinely as first-line biotherapy for the treatment of rheumatoid arthritis (RA) and spondyloarthritis (SpA: psoriatic arthritis [PsA] and ankylosing spondylitis [AS]) in patients who have failed traditional non-biologic disease-modifying anti-rheumatic drugs (DMARDs). However, about 30% of patients experience failure of first-line anti-TNF agent because of inefficacy or adverse events. This study analyzed long-term anti-TNFα drug survival in a clinical practice setting. The overall 10-year retention rate of first-line anti-TNF agent is about 23%, being significantly higher for SpA compared with RA patients. ETN is the most persistent anti-TNF with a drug survival rate significantly higher than IFX and ADA.
Keywords:
anti-tumor necrosis factor (TNF); drug survival; inflammatory arthritides.
© 2014 Wiley Periodicals, Inc.
MeSH terms
-
Adalimumab
-
Adult
-
Aged
-
Anti-Inflammatory Agents, Non-Steroidal / adverse effects
-
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
-
Antibodies, Monoclonal / adverse effects
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized / adverse effects
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Antirheumatic Agents / adverse effects
-
Antirheumatic Agents / therapeutic use*
-
Arthritis, Psoriatic / drug therapy*
-
Arthritis, Rheumatoid / drug therapy*
-
Etanercept
-
Female
-
Humans
-
Immunoglobulin G / adverse effects
-
Immunoglobulin G / therapeutic use
-
Infliximab
-
Kaplan-Meier Estimate
-
Male
-
Middle Aged
-
Receptors, Tumor Necrosis Factor / therapeutic use
-
Spondylitis, Ankylosing / drug therapy*
-
Treatment Outcome
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Substances
-
Anti-Inflammatory Agents, Non-Steroidal
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antirheumatic Agents
-
Immunoglobulin G
-
Receptors, Tumor Necrosis Factor
-
Tumor Necrosis Factor-alpha
-
Infliximab
-
Adalimumab
-
Etanercept